2-氨基-1,9-二甲基嘌呤-6-酮 | 42484-34-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 2-氨基-1,9-二甲基嘌呤-6-酮
• 英文名称: 2-amino-1,9-dimethylpurin-6-one
• 英文别名: 1,9-dimethylguanine；2-amino-1,9-dimethyl-1,9-dihydro-purin-6-one
• CAS: 42484-34-4
• 化学式: C₇H₉N₅O
• 分子量: 179.181
• InChiKey: MXLVASHNANBJDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-氨基-1,9-二甲基嘌呤-6-酮 、 chloroauric acid 在 HCl 、 NaOH 作用下， 以 水 为溶剂， 以90%的产率得到AuCl3(1,9-dimethylguanine)
  参考文献：
  名称：

  Interactions between [AuX4]− (X = Cl, CN) and cytosine and guanine model nucleobases: salt formation with (hemi-) protonated bases, coordination, and oxidative degradation of guanine

  摘要：

  Complexes of composition AuCl3L with L= 1,9-dimethylguanine (1,9-DimeG) (1), 2-amino-6-methoxy-9-methylpurine ((OMe)-Me-6-9-MeG) (2), 9-methylguanine (9-MeGH) (3), and 9-ethylguanine (9-EtGH) (4) were prepared from Na[AuCl4] or H[AuCl4] and L in water at pH 3.2 +/- 0.5. The X-ray crystal structures of 1 and 2 were determined. In both complexes, Au(III) binding is via N(7) of the purine ring. The coordination sphere of Au(III) is completed by three Cl ligands in a square plane and a weaker intermolecular contact with an adjacent molecule (Au ... Cl, 3.59(5) Angstrom (1) and 3.48(1) Angstrom (2)), thereby making each Au atom approximately square-pyramidal. In addition, three salts containing the fully or hemiprotonated model nucleobases 7,9-dimethylguanine (7,9-DimeGH), 9-MeGH and 1-methylcytosine (1-MeC) were X-ray structurally characterized: [7,9-DimeGH] [AuCl4] (5), [(9-MeGH(2)) . (9-MeGH) ] [Au(CN)(4)] (6), and [ ( 1-MeCH) . (1-MeC) ] [Au(CN)(4)] . 2H(2)O (7). Although poorly soluble in water, compounds 1-4 redissolve in a slow process that takes weeks to months with destruction of the purine skeleton and formation of guanidinium and parabanic acid derivatives as well as other products, depending upon the conditions applied. (C) 1998 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0020-1693(98)00099-1
• 作为产物：
  描述：

  2-氨基-6-甲氧基嘌呤 生成 2-氨基-1,9-二甲基嘌呤-6-酮
  参考文献：
  名称：

  KOHDA, KOHFUKU;BABA, KUNIHISA;KAWAZOE, YUTAKA, TETRAHEDRON LETT., 28,(1987) N 50, 6285-6288

  摘要：

  DOI：

文献信息

• [EN] ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'ÉCTONUCLÉOTIDASE ET LEURS MÉTHODES D'UTILISATION
  申请人：CALITHERA BIOSCIENCES INC

  公开号：WO2018119284A1

  公开（公告）日：2018-06-28

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  这项发明涉及新颖的杂环化合物及其制药制剂。该发明还涉及使用该发明的新颖杂环化合物治疗或预防癌症的方法。
• HgCl2 coordination to guanine derivatives: structural and spectroscopic studies on the interactions with 9-ethylguanine, 1,9-dimethylguanine and 2-amino-6-methoxy-9-methylpurine (6,9-dimethylguanine)
  作者：Stephan Menzer、Edda C. Hillgeris、Bernhard Lippert

  DOI：10.1016/s0020-1693(00)85606-6

  日期：1993.9

  955(2), b=17.176(6), c=21.829(9) A, Z=4) are reported. Binding of HgCl2 is through N7 of the purine bases. In 1 discrete molecules are formed, while 2 is a linear polymer with (HgCl)n chains to which the guanine bases and chloro ligands are coordinated. The solution behavior is characterized by a rapid ligand exchange and low complex formation constants, log β1=0.4 (1), 1.3 (1:1 adduct of 2) and 1.0 [HgCl2·9-EtGH]

  摘要研究了HgCl2与9-乙基鸟嘌呤，1,9-二甲基鸟嘌呤和2-氨基-6-甲氧基-9-甲基嘌呤（6,9-二甲基鸟嘌呤）的配位。配合物HgCl2（2-氨基-6-甲氧基-9-甲基-嘌呤-N7）（1）的X射线结构（单斜晶系，P21 / m，a = 10.160（3），b = 6.222（1）， c = 11.060（3）A，β= 116.11（2）°，Z = 2）和[HgCl2·（1,9-二甲基-鸟嘌呤-N7）] 2HgCl2} n（2）（斜方晶系，Pbca，a =报告了6.955（2），b = 17.176（6），c = 21.829（9）A，Z = 4）。HgCl2的结合通过嘌呤碱基的N7进行。在1个分子中形成了离散分子，而在2个分子中则是带有（Hg = Cl）n链的线性聚合物，鸟嘌呤碱基和氯配体与该聚合物配位。溶液行为的特征在于快速的配体交换和低的络合物形成常数，logβ1= 0.4（1），1
• COMPOSITION COMPRISING PURINE DERIVATIVES OR SALT THEREOF FOR PREVENTING OR TREATING ATOPIC DERMATITIS
  申请人：Daewoong Co., Ltd.

  公开号：EP2837382A1

  公开（公告）日：2015-02-18

  The present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt as an active ingredient. And also, the present invention provides a cosmetic composition for improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt; and a food (i.e., a functional food) for preventing or improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt.

  本发明提供了一种用于预防或治疗特应性皮炎的药物组合物，其活性成分包括 2-氨基-1,9-二甲基嘌呤-6-酮或其药学上可接受的盐。此外，本发明还提供了一种用于改善特应性皮炎的化妆品组合物，其中包含 2-氨基-1,9-二甲基嘌呤-6-酮或其药学上可接受的盐；以及一种用于预防或改善特应性皮炎的食品（即功能性食品），其中包含 2-氨基-1,9-二甲基嘌呤-6-酮或其药学上可接受的盐。
• Chemical reactivity of alkylguanines. I. Methylation of O6-methylguanine derivatives
  作者：Kohfuku Kohda、Kunihisa Baba、Yutaka Kawazoe

  DOI：10.1016/s0040-4039(01)91353-x

  日期：1987.1
• Photoemission properties of methyl-substituted guanines: photoelectron and fluorescence investigations of 1,9-dimethylguanine, O6,9-dimethylguanine, and 9-methylguanine
  作者：Pierre R. LeBreton、Xu Yang、Shigeyuki Urano、Sharon Fetzer、Min Yu、Nelson J. Leonard、Shiv Kumar

  DOI：10.1021/ja00162a015

  日期：1990.3